Aspira Pathlab & Diagnostics Ratios

Aspira Pathlab & Diagnostics Ltd Ratios

The Aspira Pathlab & Diagnostics Ltd Ratios page provides a complete fundamental analysis of Aspira Pathlab & Diagnostics Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Aspira Pathlab & Diagnostics Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Aspira Pathlab & Diagnostics Ltd (NSE: , BSE: 540788) is currently trading at ₹55.85, with a market capitalization of ₹574.86M. As a major player in the Health services sector and Medical/Nursing services industry, Aspira Pathlab & Diagnostics Ltd remains a key stock for fundamental analysis using Aspira Pathlab & Diagnostics Ltd Ratios.

Aspira Pathlab & Diagnostics Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Aspira Pathlab & Diagnostics Ltd P/E ratio currently stands at 43.37, making it one of the most tracked metrics in Aspira Pathlab & Diagnostics Ltd Ratios.

Historically, the Aspira Pathlab & Diagnostics Ltd P/E ratio has shown strong fluctuations:

• 2024: 43.37
• 2023: 0
• 2022: 0
• 2021: 14.96
• 2020: 19.65

The rising Aspira Pathlab & Diagnostics Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Aspira Pathlab & Diagnostics Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 7.21.

Historical P/B trend:

• 2024: 7.21
• 2023: 3.15
• 2022: 2.25
• 2021: 5.22

Aspira Pathlab & Diagnostics Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Aspira Pathlab & Diagnostics Ltd P/S ratio currently stands at 3.99, an important part of Aspira Pathlab & Diagnostics Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.99
• 2023: 2.42
• 2022: 1.98
• 2021: 3.41

The rising Aspira Pathlab & Diagnostics Ltd P/S ratio indicates improved revenue valuation by investors.

Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio (P/CF)

The Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 43.33.

Historical Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio:

• 2024: 43.33
• 2023: 24.79
• 2022: 228.78
• 2021: 38.05
• 2020: 5.44

The rising Aspira Pathlab & Diagnostics Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Aspira Pathlab & Diagnostics Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Aspira Pathlab & Diagnostics Ltd EV currently stands at ₹887.79M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 887.79M
• 2023: 333.06M
• 2022: 296.3M
• 2021: 689.77M

Aspira Pathlab & Diagnostics Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Aspira Pathlab & Diagnostics Ltd EV/EBITDA ratio is currently 24.96, a key metric in Aspira Pathlab & Diagnostics Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 24.96
• 2023: 0
• 2022: 18.60
• 2021: 10.82

Higher Aspira Pathlab & Diagnostics Ltd EV/EBITDA suggests premium valuation.

Aspira Pathlab & Diagnostics Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Aspira Pathlab & Diagnostics Ltd D/E ratio is currently 0.26, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.26
• 2023: 0.27
• 2022: 0.26
• 2021: 0.31

Aspira Pathlab & Diagnostics Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Aspira Pathlab & Diagnostics Ltd ROE currently stands at 18.13%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 18.13
• 2023: -23.34
• 2022: -0.69
• 2021: 42.26

Aspira Pathlab & Diagnostics Ltd maintains stable profitability levels.

Aspira Pathlab & Diagnostics Ltd Ratios Analysis Summary

The Aspira Pathlab & Diagnostics Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Aspira Pathlab & Diagnostics Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Aspira Pathlab & Diagnostics Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.